SCHEMBL15566293

SCHEMBL15566293

CC(C)(C)n1ncc(OCc2cccc(OCCCF)c2)c(Cl)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 2/20 0.53
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
GALR3 O60755 1/20 0.39
NR2F2 P24468 1/20 0.39
GPR183 P32249 1/20 0.39
RAB9A P51151 1/20 0.39
GPR35 Q9HC97 1/20 0.39
MAPK1 P28482 2/20 0.37
TSHR P16473 1/20 0.37
MAPK14 Q16539 4/20 0.37
GAA P10253 1/20 0.35
PKM P14618 1/20 0.35
MAOA P21397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15566575 0.95 SMN1; SMN2 (0.53) SMN1; SMN2LMNAHPGDHTTATM
SCHEMBL16901950 0.91 SMN1; SMN2 (0.53) SMN1; SMN2LMNAHPGDHTTATM
SCHEMBL16901943 0.90 SMN1; SMN2 (0.54) SMN1; SMN2LMNAHPGDHTTATM
SCHEMBL15596692 0.89 SMN1; SMN2 (0.53) SMN1; SMN2LMNAHPGDHTTATM
SCHEMBL12722501 0.88 SMN1; SMN2 (0.46) SMN1; SMN2LMNAHPGDHTTATM
SCHEMBL1627237 0.88 SMN1; SMN2 (0.46) SMN1; SMN2LMNAHPGDHTTATM
SCHEMBL15596716 0.86 SMN1; SMN2 (0.48) SMN1; SMN2LMNAHPGDHTTATM
SCHEMBL15566349 0.86 SMN1; SMN2 (0.49) SMN1; SMN2LMNAHPGDHTTATM
SCHEMBL15564831 0.85 SMN1; SMN2 (0.50) SMN1; SMN2LMNAHPGDHTTATM
SCHEMBL15596648 0.85 SMN1; SMN2 (0.43) SMN1; SMN2LMNAHPGDHTTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 US disclosed
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2024-03-28 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
CN-113754589-A Compositions, methods, and systems for synthesis and use of contrast agents 蓝瑟斯医学影像公司 2021-12-07 CN disclosed
CN-107311935-B Compositions, methods, and systems for synthesis and use of contrast agents 蓝瑟斯医学影像公司 2021-10-08 CN disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 US disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 US disclosed
EP-3653621-A1 APPARATUS FOR SYNTHESIZING THE IMAGING AGENT 4-CHLORO-2-(1,1-DIMETHYLETHYL)-5-[[4-[[2-(FLUORO-[18F])ETHOXY]METHYL]PHENYL]METHOXY]-3(2H)-PYRIDAZINONE (FLUORPIRIDAZ [18F]) Lantheus Medical Imaging, Inc. (US) 2020-05-20 EP disclosed
US-20170151353-A9 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2017-06-01 US disclosed
US-9555138-B2 2017-01-31 US disclosed
US-9555138-B2 2017-01-31 US disclosed
US-9555138-B2 2017-01-31 US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 US disclosed
EP-2882719-A2 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS Lantheus Medical Imaging, Inc. (US) 2015-06-17 EP disclosed
WO-2014026079-A2 COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-02-13 WO disclosed
WO-2014026079-A2 COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS TNNI3, FABP3, TNNT2 SMN1; SMN2 420/4885LMNA 1473/4885HPGD 2331/4885
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 SMN1; SMN2 699/4885LMNA 1449/4885HPGD 2765/4885
US-20170151353-A9 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS TNNI3, FABP3, TNNT2 SMN1; SMN2 420/4885LMNA 1473/4885HPGD 2331/4885
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 SMN1; SMN2 699/4885LMNA 1449/4885HPGD 2765/4885
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 SMN1; SMN2 699/4885LMNA 1449/4885HPGD 2765/4885
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents FABP3, TNNI3, TNNT2 SMN1; SMN2 699/4885LMNA 1449/4885HPGD 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.